20152 WEBCAST: The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant
The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians.
This activity can be accessed using the following URL: www.peerview.com/WRR
This activity has been designed to meet the educational needs of hematologistoncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of AML.
Upon completion of this activity, participants should be better able to:
- Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML
- Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies
- Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML
This activity is supported by educational grants from Actinium Pharmaceuticals, Celgene Corporation, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals, Inc.
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Harry P. Erba, MD, PhD Professor of Medicine Director, Leukemia Program Duke University Medical Center Durham, North Carolina
Harry P. Erba, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Agios, Inc.; Celgene Corporation; Daiichi Sankyo Company, Limited; Dava Oncology; GlycoMimetics; Incyte Corporation; Jazz Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. Speakers Bureau participant with Agios, Inc.; Celgene Corporation; Incyte Corporation; Jazz Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. Other Financial or Material Support from Covance Inc./AbbVie Inc. in the form of Chair, Independent Review Committee for AbbVie Phase III Studies.
James M. Foran, MD, FRCPC Associate Professor of Oncology Chair, Acute Leukemia & Myeloid Neoplasm Disease Group, Mayo Clinic Cancer Center Associate Chair of Medicine [Research], Mayo Clinic Jacksonville, Florida
James M. Foran, MD, FRCPC, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer, Inc. Grant/Research Support from AbbVie Inc.; Actinium Pharmaceuticals, Inc.; Aprea Therapeutics; Aptose Biosciences Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; H3 Biomedicine Inc.; Kura Oncology, Inc.; Leukemia and Lymphoma Society; Mellennium; Takeda Pharmaceutical Company Limited; Tolero Pharmaceuticals; Trillium Therapeutics Inc.; and Xencor, Inc. Honoraria from Agios, Inc.; American Society of Hematology; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer, Inc.
Carmine DeLuca PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
he Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Providership, Credit, and Support This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.